Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable HER inhibitor (Pan) Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited proliferation and increased apoptosis in several human colorectal tumor cell lines in culture (PMID: 21617858). 21617858
Unknown unknown lung non-small cell carcinoma not applicable HER inhibitor (Pan) Afatinib + Nimotuzumab Phase Ib/II Actionable In a Phase I/II trial, Gilotrif (afatinib) and Nimotuzumab combination treatment resulted in a median progression-free survival of 4.0 months, an overall survival of 11.7 months, and overall response rate of 23% (10/44) in non-small cell lung cancer patients with acquired resistance to Iressa (gefitinib) or Tarceva (erlotinib) (PMID: 26667485). 26667485
Unknown unknown Advanced Solid Tumor not applicable HER inhibitor (Pan) Afatinib + Vinorelbine Phase I Actionable In a Phase I trial, the combination of Gilotrif (afatinib) and Navelbine (vinorelbine) resulted in clinical efficacy, including two breast cancer patients with a partial response and stable disease in eight patients with advanced solid tumors (PMID: 26254023). 26254023
Unknown unknown breast cancer not applicable HER inhibitor (Pan) Afatinib + Vinorelbine Phase I Actionable In a Phase I trial, the combination of Gilotrif (afatinib) and Navelbine (vinorelbine) resulted in clinical efficacy, including two breast cancer patients with a partial response and stable disease in eight patients with advanced solid tumors (PMID: 26254023). 26254023
Unknown unknown Advanced Solid Tumor not applicable HER inhibitor (Pan) Poziotinib Phase I Actionable In a Phase I trial, Poziotinib (HM781-36B) displayed favorable pharmacokinetics in patients with advanced solid tumors (PMID: 25377158). 25377158
Unknown unknown Her2-receptor positive breast cancer not applicable HER2 (ERBB2) Antibody Abemaciclib + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the addition of Abemaciclib (LY2835219) to Tykerb (lapatinib) treatment enhanced growth inhibitory effects of Tykerb (lapatinib)-resistant ERBB2 (HER2)-receptor positive breast cancer cells in culture (PMID: 26977878). 26977878
Unknown unknown colon adenocarcinoma not applicable HER2 (ERBB2) Antibody Capecitabine + Lapatinib Phase II Actionable In a Phase II trial, Tykerb (lapatinib) combined with Xeloda (capecitabine) demonstrated safety, but failed to show efficacy in patients with advanced refractory colorectal cancer (PMID: 22811876). 22811876
Unknown unknown stomach cancer not applicable HER2 (ERBB2) Antibody Capecitabine + Lapatinib Phase II Actionable In a Phase II trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in partial response in 17.9% (12/67) and stable disease in 46.3% (31/67) of gastric cancer patients regardless of their ERBB2 (HER2) status, although increased Erbb3 (Her3) expression level correlated with higher response rate (PMID: 27325685). 27325685
Unknown unknown breast cancer not applicable HER2 (ERBB2) Antibody CPI-455 + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, a breast cancer cell line treated with Tykerb (lapatinib) demonstrated increased sensitivity when co-treated with CPI-455 in culture, resulting in decreased survival of cells, in particular the cells that eventually develop drug resistance (PMID: 27214401). 27214401
Unknown unknown Advanced Solid Tumor not applicable HER2 (ERBB2) Antibody Lapatinib + MK2206 Phase I Actionable In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 4 months in 9% (2/23) of patients with advanced solid tumors (PMID: 27026198). 27026198
Unknown unknown Her2-receptor positive breast cancer not applicable HER2 (ERBB2) Antibody Abemaciclib + Trastuzumab Preclinical - Pdx & cell culture Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Abemaciclib (LY2835219) resulted in tumor growth regresssion in an ERBB2 (HER2)-receptor positive breast cancer treatment refractory patient derived xenograft model and in ERBB2 (HER2)-receptor positive cultured cells, resulted in decreased cell viability (PMID: 26977878). 26977878
Unknown unknown stomach cancer not applicable HER2 (ERBB2) Antibody ALX148 + Trastuzumab Phase I Actionable In a Phase I trial, ALX148 and Herceptin (trastuzumab) combination treatment resulted in a partial response in 19% (4/21) and stable disease in 29% (6/21) of patients with gastric or gastroesophageal junction cancer that progressed on chemotherapy (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 2514-2514; NCT03013218). detail...
Unknown unknown gastroesophageal junction adenocarcinoma not applicable HER2 (ERBB2) Antibody ALX148 + Trastuzumab Phase I Actionable In a Phase I trial, ALX148 and Herceptin (trastuzumab) combination treatment resulted in a partial response in 19% (4/21) and stable disease in 29% (6/21) of patients with gastric or gastroesophageal junction cancer that progressed on chemotherapy (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 2514-2514; NCT03013218). detail...
Unknown unknown follicular lymphoma not applicable HER2 Inhibitor APG-2575 + Ibrutinib Preclinical - Cell line xenograft Actionable In a preclinical study, APG-2575 and Imbruvica (ibrutinib) combination therapy exhibited synergistic antitumor activity in a cell-line xenograft model of follicular lymphoma (Cancer Res July 1 2019 (79) (13 Supplement) 2058). detail...
Unknown unknown diffuse large B-cell lymphoma not applicable HER2 Inhibitor APG-2575 + Ibrutinib Preclinical - Cell line xenograft Actionable In a preclinical study, APG-2575 and Imbruvica (ibrutinib) combination therapy exhibited synergistic antitumor activity and induced tumor regression (80% complete and 20% partial) in cell-line xenograft models of diffuse large B-cell lymphoma (Cancer Res July 1 2019 (79) (13 Supplement) 2058). detail...
Unknown unknown mantle cell lymphoma not applicable HER2 Inhibitor Buparlisib + Ibrutinib Phase Ib/II Actionable In a Phase I/II trial, Buparlisib (BKM120) and Imbruvica (ibrutinib) combination treatment resulted in a best overall response rate of 88% (15/17, 11 complete response, 4 partial response) in patients with relapsed/refractory mantle cell lymphoma (J Clin Oncol 36, 2018 (suppl; abstr 7520); NCT02756247). detail...
Unknown unknown follicular lymphoma not applicable HER2 Inhibitor Buparlisib + Ibrutinib Phase Ib/II Actionable In a Phase I/II trial, Buparlisib (BKM120) and Imbruvica (ibrutinib) combination treatment resulted in a best overall response rate of 20% (1/5, 1 complete response) in patients with relapsed/refractory follicular lymphoma (J Clin Oncol 36, 2018 (suppl; abstr 7520); NCT02756247). detail...
Unknown unknown diffuse large B-cell lymphoma not applicable HER2 Inhibitor Buparlisib + Ibrutinib Phase Ib/II Actionable In a Phase I/II trial, Buparlisib (BKM120) and Imbruvica (ibrutinib) combination treatment resulted in a best overall response rate of 31% (4/13, 3 complete response, 1 partial response) in patients with relapsed/refractory diffuse large B-cell lymphoma (J Clin Oncol 36, 2018 (suppl; abstr 7520); NCT02756247). detail...
Unknown unknown CLL/SLL not applicable HER2 Inhibitor Ibrutinib FDA approved Actionable In a Phase III trial (RESONATE-2) that supported FDA approval, Imbruvica (ibrutinib) treatment resulted in a greater median progression-free survival (not reached vs 18.9 months, HR=0.16, p<0.001) and response rate (86% vs 35%, p<0.001) when compared to chlorambucil treatment in patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) aged 65 or older (PMID: 26639149; NCT01722487). detail... 26639149
Unknown unknown CLL/SLL not applicable HER2 Inhibitor Ibrutinib FDA approved Actionable In a Phase III trial (RESONATE) that supported FDA approval, treatment with Imbruvica (ibrutinib) in chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) patients resulted in improved progression-free survival compared to treatment with Arzerra (ofatumumab) (median duration not reached vs. 8.1 months), and an overall response rate of 43% (83/195) versus 4% (8/196) with Arzerra (ofatumumab) (PMID: 24881631; NCT01578707). detail... 24881631
Unknown unknown CLL/SLL not applicable HER2 Inhibitor Ibrutinib FDA approved Actionable In a Phase III trial (RESONATE) that supported FDA approval, treatment with Imbruvica (ibrutinib) in chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) patients with del 17p resulted in improved progression-free survival compared to Arzerra (ofatumumab) (40.6 vs. 8.1 months), and improved overall response rate (47.6%, 30/63 vs 4.7%, 3/64) (PMID: 31512258; NCT01578707). 31512258 detail...
Unknown unknown mantle cell lymphoma not applicable HER2 Inhibitor Ibrutinib FDA approved Actionable In a Phase II trial (Study 1104) that supported FDA approval, Imbruvica (ibrutinib) treatment resulted in a response rate of 68% (75/111, complete response 21%, partial response 47%), with an estimated median progression-free survival of 13.9 months in patients with relapsed or refractory mantle-cell lymphoma (PMID: 23782157, NCT01236391). 23782157 detail...
Unknown unknown chronic lymphocytic leukemia not applicable HER2 Inhibitor Ibrutinib Clinical Study Actionable In a clinical study, treatment with Imbruvica (ibrutinib) resulted in a discontinuation-free survival rate at 1 year of 73.7% (232/315) and an absolute 1 year survival rate of 83.3% (264/315) in patients with relapsed or refractory chronic lymphocytic leukemia (PMID: 27756834). 27756834
Unknown unknown Waldenstroem's macroglobulinemia not applicable HER2 Inhibitor Ibrutinib FDA approved Actionable In a Phase II trial that supported FDA approval, Ibruvica (ibrutinib) treatment resulted in an overall response rate of 90.5% and a major response rate of 73.0% in patients with previously treated Waldenstroem's macroglobulinemia (PMID: 25853747; NCT01614821). 25853747 detail...
Unknown unknown hairy cell leukemia not applicable HER2 Inhibitor Ibrutinib Preclinical - Cell culture Actionable In a preclinical study, Imbruvica (ibrutinib) inhibited Btk activity and B-cell receptor signaling, thereby resulting in inhibition of cell proliferation and decreased survival of human hairy cell leukemia cells in culture (PMID: 24697238). 24697238
Unknown unknown diffuse large B-cell lymphoma not applicable HER2 Inhibitor Ibrutinib Phase II Actionable In a Phase II trial, Imbruvica (ibrutinib) treatment demonstrated preferential efficacy in the ABC subtype of diffuse large B-cell lymphoma (DLBCL) compared to the GCB subtype, resulted in complete response in 8% (2/25) and partial response in 32% (8/25) of ABC DLBCL patients, but only partial response in 5.3% (1/19) of GCB DLBCL patients (Blood 2012, 120 (21): 686). detail...
Unknown unknown marginal zone B-cell lymphoma not applicable HER2 Inhibitor Ibrutinib FDA approved Actionable In a Phase II trial that supported FDA approval, Imbruvica (ibrutinib) treatment resulted in an objective response rate of 48% (29/60) in patients with previously treated marginal zone lymphoma, with a median progression-free survival of 14.2 months (PMID: 28167659; NCT01980628). 28167659 detail...
Unknown unknown central nervous system lymphoma not applicable HER2 Inhibitor Ibrutinib Phase I Actionable In a Phase I trial, Imbruvica (ibrutinib) treatment resulted in antitumor efficacy in 77% (10/13) of patients with primary central nervous system lymphoma, demonstrating a complete response in five patients and a partial response in five patients (PMID: 28619981). 28619981
Unknown unknown mantle cell lymphoma not applicable HER2 Inhibitor Ibrutinib + ONC201 Preclinical - Patient cell culture Actionable In a preclinical study, the combination of ONC201 and Imbruvica (ibrutinib) induced apoptosis in primary mantle cell lymphoma samples in culture, including Imbruvica (ibrutinib)-resistant samples, with greater efficacy than either agent alone (PMID: 26884599). 26884599
Unknown unknown mantle cell lymphoma not applicable HER2 Inhibitor Ibrutinib + Palbociclib Phase I Actionable In a Phase I trial, Imbruvica (ibrutinib) and Ibrance (palbociclib) combination treatment resulted in an overall response rate of 67%, a complete response rate of 37%, and a two year progression-free survival in 59.4% of patients with previously treated mantle cell lymphoma, with a median follow up of 25.6 months (PMID: 30692121; NCT02159755). detail... 30692121
Unknown unknown diffuse large B-cell lymphoma not applicable HER2 Inhibitor Ibrutinib + PQR309 Preclinical - Cell line xenograft Actionable In a preclinical study, the combination therapy of PQR309 and Imbruvica (ibrutinib) led to a synergistic effect in 6/7 diffuse large B-cell lymphoma (DLBCL) cell lines in culture, and the effect was confirmed in a DLBCL cell line xenograft model (PMID: 29066507). 29066507
Unknown unknown CLL/SLL not applicable HER2 Inhibitor Ibrutinib + Rituximab FDA approved Actionable In a Phase III trial that supported FDA approval, combination of Imbruvica (ibrutinib) and Rituxan (rituximab) resulted in superior progression-free survival at 3 years (89.4% vs 72.9%, HR=0.35, p<0.001) and overall survival at 3 years (98.8% vs 91.5%, HR=0.17, p<0.001) compared to chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (PMID: 31365801; NCT02048813). detail... 31365801
Unknown unknown diffuse large B-cell lymphoma not applicable HER2 Inhibitor Ibrutinib + SEL24-B489 Preclinical Actionable In a preclinical study, SEL24-B489 demonstrated a synergistic effect when combined with Ibruvica (ibrutinib) in diffuse large B-cell lymphoma cells in culture, resulting in cell growth inhibition ((Blood 126 (23):706.December 2015). detail...
Unknown unknown diffuse large B-cell lymphoma not applicable HER2 Inhibitor Ibrutinib + Silmitasertib Preclinical - Cell culture Actionable In a preclinical study, the combination of Silmitasertib (CX-4945) and Imbruvica (ibrutinib) worked synergistically to decrease cell viability and resulted in increased apoptosis and decreased AKT phosphorylation in ABC and GCB-type diffuse large B-cell lymphoma cell lines in culture (PMID: 28460620). 28460620
Unknown unknown B-cell lymphoma not applicable HER2 Inhibitor Ibrutinib + Ublituximab + Umbralisib Phase I Actionable In a Phase I trial, Imbruvica (Ibrutinib), TGR01201, and Ublituximab combination treatment resulted in complete response in 14% (1/7) and partial response in 71% of patients with relapsed B-cell lymphoas within 8 weeks of treatment (J Clin Oncol 33, 2015 (suppl; abstr 8501)). detail...
Unknown unknown colorectal cancer not applicable HER2 Inhibitor Ibrutinib + unspecified CTLA4 antibody Preclinical Actionable In a preclinical study, the combination of Imbruvica (ibrutinib) and an anti-CTLA4 antibody resulted in complete tumor regression in colorectal cancer mouse models (Cancer Res 2016;76(14 Suppl):Abstract nr 2321). detail...
Unknown unknown Advanced Solid Tumor not applicable HER2 Inhibitor Ibrutinib + unspecified PD-L1 antibody Preclinical Actionable In a preclinical study, the combination treatment of Imbruvica (ibrutinib) and an anti-PD-L1 antibody in mouse models with advanced solid tumors resulted in antitumor efficacy, including decreased tumor size, minimized metastasis, and improved survival in triple-receptor negative breast cancer mouse models, and a 30% cure rate and improved survival in colon cancer mouse models (PMID: 25730880). 25730880
Unknown unknown follicular lymphoma not applicable HER2 Inhibitor Ibrutinib + Venetoclax Preclinical - Cell culture Actionable In a preclinical study, the combination of Imbruvica (ibrutinib) and Venclexta (venetoclax) resulted in a synergistic effect, demonstrating growth suppression in follicular lymphoma cell lines in culture (PMID: 28428442). 28428442
Unknown unknown chronic lymphocytic leukemia not applicable HER2 Inhibitor Ibrutinib + Venetoclax Phase II Actionable In a Phase II trial, Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy resulted in a response rate of 100% (14/14, 9 complete response, 5 partial response) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients, and a response rate of 100% (16/16, 9 complete response, 7 partial response) in untreated patients with high-risk features including del 17p, TP53 mutations, and del 11q (ASH, 59th Annual Meeting and Exposition, Dec 2017, Abstract 429; NCT02756897). detail...
Unknown unknown diffuse large B-cell lymphoma not applicable HER2 Inhibitor Ibrutinib + Venetoclax Preclinical - Cell culture Actionable In a preclinical study, the combination of Imbruvica (ibrutinib) and Venclexta (venetoclax) resulted in a synergistic effect, demonstrating growth suppression in germinal center B-cell diffuse large B-cell lymphoma (DLBCL) cell lines in culture, increased apoptotic activity and inhibition of colony formation in activated B-cell (ABC) DLBCL cell lines, and complete tumor growth inhibition in ABC-DLBCL cell line xenograft models (PMID: 28428442). 28428442
Unknown unknown lymphoblastic lymphoma not applicable HER2 Inhibitor Ibrutinib + VLX1570 Preclinical - Cell culture Actionable In a preclinical study, the combination of Imbruvica (ibrutinib) and VLX1570 worked synergistically to reduce viability of an Imbruvica (ibrutinib)-resistant Waldenstrom macroglobulinemia cell line in culture (PMID: 27813535). 27813535
Unknown unknown Advanced Solid Tumor not applicable HER2 Inhibitor Neratinib + Temsirolimus Phase I Actionable In a Phase I study, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in multiple solid tumor types, including breast cancer and NSCLC (PMID: 24323026). 24323026
Unknown unknown Advanced Solid Tumor not applicable HER2 Inhibitor BMS-690514 Phase Ib/II Actionable In a Phase Ib/II trial, BMS-690514 demonstrated safety and preliminary efficacy in patients with advanced solid tumors (PMID: 23490650). 23490650
Unknown unknown lung non-small cell carcinoma not applicable HER2 Inhibitor BMS-690514 Phase Ib/II Actionable In a Phase 1b/II trial, BMS-690514 was demonstrated to be safe and efficacious in patients with NSCLC (PMID: 23490650). 23490650
Unknown unknown Advanced Solid Tumor not applicable HER2 Inhibitor AC480 Phase I Actionable In a Phase I trial, AC480 demonstrated safety and potential efficacy in patients with several solid tumor types (PMID: 21576284). 21576284
Unknown unknown stomach cancer not applicable HER2 Inhibitor CUDC-101 Phase I Actionable In a Phase I trial, a gastric cancer patient treated with CUDC-101 demonstrated a partial response for 57 days, in which the tumor regressed by 56% (PMID: 25107918). 25107918
Unknown unknown Advanced Solid Tumor not applicable HER2 Inhibitor JNJ-26483327 Phase I Actionable In a Phase I clinical trial, JNJ-26483327 was well-tolerated in patients with a range of advanced solid tumors, and demonstrated preliminary anti-tumor activity with 32% (6/19) of patients achieving stable disease for greater than 2 cycles (PMID: 20823884). 20823884
Unknown unknown stomach cancer not applicable HER2 Inhibitor JNJ-26483327 Preclinical Actionable In a preclinical study, human gastric cancer cells demonstrated sensitivity to JNJ-26483327 (PMID: 19584230). 19584230
Unknown unknown Advanced Solid Tumor not applicable HER2 Inhibitor Varlitinib Phase I Actionable In a Phase I clinical trial, Varlitinib (ARRY-334543) demonstrated safety and some preliminary anti-tumor activity in patients with advanced solid tumors (Mol Cancer Ther 2009;8(12 Suppl):B54). detail...
Unknown unknown gastroesophageal cancer not applicable HER2 Inhibitor Capecitabine + Oxaliplatin + Sapitinib Phase I Actionable In a Phase I trial, the addition of Sapitinib (AZD-8931) with chemotherapy, Eloxatin (oxaliplatin), and Xeloda (capecitabine), versus chemotherapy alone in patients with esophagogastric cancer resulted in a six month progression-free survival of 85% (N=20) and 100% (N=10), and an overall survival of 80% and 100% at 12 months and 64% and 90% at 24 months, respectively (PMID: 31765988). 31765988
Unknown unknown stomach cancer not applicable HER2 Inhibitor Cisplatin + Fluorouracil + Sapitinib Preclinical - Pdx Actionable In a preclinical study, Sapitinib (AZD8931), in combination with Platinol (cisplatin) and Adrucil (fluorouracil), demonstrated safety and an additive effect in a primary gastric cancer xenograft model (Cancer Res April 15, 2013 73; 2090). detail...
Unknown unknown Advanced Solid Tumor not applicable HER2 Inhibitor Sapitinib Preclinical - Cell line xenograft Actionable In a preclinical study, Sapitinib (AZD8931) inhibited EGFR, ERBB2 (HER2), and ERBB3 (HER3) kinase activity, and inhibited tumor growth in several cell line xenograft models, including breast, NSCLC, colorectal, and head and neck squamous cell carcinoma xenograft models (PMID: 20145185). 20145185
Clinical Trial Phase Therapies Title Recruitment Status
NCT02751528 Phase I ETBX-021 QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer Active, not recruiting
NCT01596751 Phase Ib/II Eribulin Pexidartinib Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer Completed
NCT01622868 Phase II Lapatinib Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer Active, not recruiting
NCT04243616 Phase II Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer Recruiting
NCT04209465 Phase I BDTX-189 A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. Recruiting
NCT03821233 Phase I ZW49 A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers Recruiting
NCT00968968 Phase III Trastuzumab Lapatinib + Trastuzumab Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone Terminated
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Active, not recruiting
NCT03387553 Phase I HER2-pulsed DC1 vaccine HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer Recruiting
NCT00194714 Phase Ib/II HER2 Vaccine Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Active, not recruiting
NCT03587740 Phase II Ado-trastuzumab emtansine ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer Recruiting
NCT04134884 Phase I ASTX727 + Talazoparib Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer Recruiting
NCT03135171 Phase I Pertuzumab + Tocilizumab + Trastuzumab Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab Recruiting
NCT03505710 Phase II Trastuzumab deruxtecan DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer Recruiting
NCT01872260 Phase I Alpelisib + Letrozole Alpelisib + Letrozole + Ribociclib Letrozole + Ribociclib Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Active, not recruiting
NCT04172597 Phase II Poziotinib A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Recruiting
NCT01522768 Phase II Afatinib + Paclitaxel Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer Active, not recruiting
NCT00411788 Phase II Sirolimus + Trastuzumab A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer Completed
NCT04215146 Phase II Paclitaxel Avelumab + Paclitaxel + Pelareorep Paclitaxel + Pelareorep A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Recruiting
NCT01275677 Phase III Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab Cyclophosphamide + Docetaxel Cyclophosphamide + Docetaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Active, not recruiting
NCT04298918 Phase Ib/II Ado-trastuzumab emtansine + Venetoclax Ado-trastuzumab emtansine A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer Recruiting
NCT02073916 Phase I Ado-trastuzumab emtansine + Lapatinib + Nab-paclitaxel TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer Completed
NCT01466972 Phase II Pazopanib Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib Completed
NCT02693535 Phase II Cobimetinib + Vemurafenib Regorafenib Ipilimumab + Nivolumab Palbociclib Afatinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Crizotinib Abemaciclib Sunitinib Olaparib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT03364348 Phase I Trastuzumab + Utomilumab Ado-trastuzumab emtansine + Utomilumab 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Recruiting
NCT04294225 Phase II Anastrozole + Letrozole Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer Recruiting
NCT02892123 Phase I Capecitabine + ZW25 ZW25 Paclitaxel + ZW25 Vinorelbine + ZW25 Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers Recruiting
NCT02139358 Phase Ib/II Gemcitabine + Pertuzumab + Trastuzumab Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Active, not recruiting
NCT02152943 Phase I Everolimus + Letrozole + Trastuzumab Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Active, not recruiting
NCT03696030 Phase I HER2 CAR-T cells HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases Recruiting
NCT03501979 Phase II Capecitabine + Trastuzumab + Tucatinib Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD Recruiting
NCT02595905 Phase II Cisplatin Cisplatin + Veliparib Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Active, not recruiting
NCT04296942 Phase I FPV-Brachyury + M7824 + MVA-BN-Brachyury Ado-trastuzumab emtansine + Entinostat + FPV-Brachyury + M7824 + MVA-BN-Brachyury Ado-trastuzumab emtansine + FPV-Brachyury + M7824 + MVA-BN-Brachyury BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) Not yet recruiting
NCT04379596 Phase II Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Cisplatin + Trastuzumab Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab Fluorouracil + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Durvalumab + Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab deruxtecan Capecitabine + Oxaliplatin + Trastuzumab deruxtecan Durvalumab + Fluorouracil + Trastuzumab deruxtecan Capecitabine + Durvalumab + Trastuzumab deruxtecan Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03) (DG-03) Recruiting
NCT04120246 Phase I alpha-TEA + Trastuzumab Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer Recruiting
NCT02213042 Phase II Lapatinib + Trastuzumab Trastuzumab Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Completed
NCT02650752 Phase I Capecitabine + Lapatinib Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases Active, not recruiting
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting
NCT01934894 Phase II Cabazitaxel + Lapatinib Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases Terminated
NCT04108858 Phase Ib/II Copanlisib + Pertuzumab + Trastuzumab Pertuzumab + Trastuzumab Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer Recruiting
NCT03377387 Phase Ib/II Capecitabine + Neratinib Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer Recruiting
NCT02605486 Phase Ib/II Bicalutamide + Palbociclib Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) Recruiting
NCT02066532 Phase Ib/II Ruxolitinib + Trastuzumab Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Active, not recruiting
NCT01148849 Phase I Margetuximab Safety Study of MGAH22 in HER2-positive Carcinomas Active, not recruiting
NCT01526473 Phase I AVX901 A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 Completed
NCT02073487 Phase II Paclitaxel Ado-trastuzumab emtansine + Lapatinib Lapatinib + Trastuzumab Nab-paclitaxel Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel Completed
NCT04147819 Phase I BAY2701439 A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein Recruiting
NCT02726399 Phase II Capecitabine + Cisplatin Ramucirumab + Trastuzumab Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer Terminated
NCT02564900 Phase I Trastuzumab deruxtecan Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Active, not recruiting
NCT02038010 Phase I Ado-trastuzumab emtansine + Alpelisib BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx Completed
NCT02187744 Phase III Carboplatin + Docetaxel + Trastuzumab A Study Of PF-05280014 Or Trastuzumab Plus Taxotere&#174; And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) Completed
NCT02060253 Phase I Ganetespib + Paclitaxel + Trastuzumab Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer Completed
NCT04513665 Phase II ZW25 ZW25 in Women With Endometrial Cancers Recruiting
NCT04224272 Phase II Fulvestrant + Palbociclib + ZW25 A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer Recruiting
NCT01857193 Phase Ib/II Everolimus + Exemestane + Ribociclib Exemestane + Ribociclib Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Completed
NCT01912963 Phase II Eribulin Pertuzumab Trastuzumab Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Terminated
NCT01989676 Phase III Paclitaxel + Trastuzumab Paclitaxel + Trazimera A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) Completed
NCT01118975 Phase Ib/II Lapatinib + Vorinostat GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers Terminated
NCT03765983 Phase II GDC-0084 + Trastuzumab GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases Recruiting
NCT03523585 Phase III Trastuzumab deruxtecan Capecitabine + Lapatinib Capecitabine + Trastuzumab DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Recruiting
NCT04539938 Phase II Trastuzumab deruxtecan + Tucatinib A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) Recruiting
NCT02091141 Phase II Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Active, not recruiting
NCT04430738 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers Recruiting
NCT04460456 Phase I SBT6050 A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors Recruiting
NCT02500199 Phase I Pyrotinib Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Active, not recruiting
NCT04329065 Phase II Paclitaxel + Pertuzumab + pUMVC3-IGFBP2-HER2-IGF1R vaccine + Trastuzumab Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer Not yet recruiting
NCT02063724 Phase I HER2-pulsed DC1 vaccine HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant) Active, not recruiting
NCT04510285 Phase II Pembrolizumab + Trastuzumab Trastuzumab Study of Pembrolizumab Plus Trastuzumab or Trastuzumab Alone After Surgery in Patients With Esophagogastric Tumors Recruiting
NCT03429101 Phase I Ado-trastuzumab emtansine + Poziotinib A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer Terminated
NCT02673398 Phase II Neratinib Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer Active, not recruiting
NCT02954536 Phase II Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer Active, not recruiting
NCT04512261 Phase Ib/II Pembrolizumab + Trastuzumab + Tucatinib TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Women With HER2-Positive Breast Cancer Brain Metastases (TOPAZ) Not yet recruiting
NCT01808573 Phase III Capecitabine + Lapatinib Capecitabine + Neratinib A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA) Completed
NCT04509596 Phase I DZD1516 + Trastuzumab Capecitabine + DZD1516 Ado-trastuzumab emtansine + DZD1516 Capecitabine + DZD1516 + Trastuzumab DZD1516 DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer Not yet recruiting
NCT03289039 Phase II Neratinib Fulvestrant + Neratinib Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer Active, not recruiting
NCT00651976 Phase I Letrozole Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery Terminated
NCT01924351 Phase II HER2-positive Breast Cancer With Brain Metastasis (GCC 1345) Withdrawn
NCT01973309 Phase I Paclitaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer Completed
NCT04042701 Phase I Pembrolizumab + Trastuzumab deruxtecan DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Recruiting
NCT02789657 Phase II Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. Active, not recruiting
NCT04450732 Phase I GQ1001 Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Recruiting
NCT03523572 Phase I Nivolumab + Trastuzumab deruxtecan Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer Recruiting
NCT03630809 Phase II HER2-pulsed DC1 vaccine Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 Recruiting
NCT03417544 Phase II Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC Active, not recruiting
NCT03094052 Phase II Neratinib Loperamide Crofelemer Neratinib + Trastuzumab Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Neratinib, With or Without Trastuzumab Recruiting
NCT03846583 Phase I Abemaciclib + Trastuzumab + Tucatinib Tucatinib + Abemaciclib + Herceptin for HER2+ MBC Not yet recruiting
NCT02659514 Phase II Poziotinib Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer Active, not recruiting
NCT02623972 Phase II Cyclophosphamide + Doxorubicin + Eribulin A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Recruiting
NCT04395508 Expanded access Pertuzumab + Trastuzumab An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic Available
NCT03414658 Phase II Avelumab + Trastuzumab + Utomilumab + Vinorelbine Avelumab + Trastuzumab + Vinorelbine Avelumab + Trastuzumab + Utomilumab Trastuzumab + Vinorelbine The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Recruiting
NCT03734029 Phase III Trastuzumab deruxtecan Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] Recruiting
NCT04481113 Phase I Abemaciclib + Niraparib Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer Not yet recruiting
NCT01730833 Phase II Paclitaxel + Pertuzumab + Trastuzumab Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer Active, not recruiting
NCT01875666 Phase I Lapatinib + Trastuzumab Trastuzumab Pertuzumab Pertuzumab + Trastuzumab Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib Completed
NCT02189174 Phase Ib/II CLR457 Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies Terminated
NCT03804515 Phase I Poziotinib A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib Active, not recruiting
NCT03602079 Phase Ib/II A166 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting
NCT04351230 Phase II Abemaciclib + Ado-trastuzumab emtansine Ado-trastuzumab emtansine Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer Not yet recruiting
NCT03530696 Phase II Ado-trastuzumab emtansine Ado-trastuzumab emtansine + Palbociclib T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer (T-DM1) Recruiting
NCT01983501 Phase I Ado-trastuzumab emtansine + Tucatinib A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer Completed
NCT03716180 Phase I Paclitaxel + Pertuzumab + Trastuzumab DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC Active, not recruiting
NCT03043313 Phase II Trastuzumab + Tucatinib Tucatinib Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer Recruiting
NCT01922921 Phase Ib/II HER-2/neu intracellular domain protein + Pertuzumab + Polysaccharide-K + Trastuzumab HER-2/neu intracellular domain protein + Pertuzumab + Trastuzumab Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy Unknown status
NCT03366844 Phase Ib/II Pembrolizumab Breast Cancer Study of Preoperative Pembrolizumab + Radiation Recruiting
NCT03125928 Phase II Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer Recruiting
NCT01160211 Phase III Lapatinib + Trastuzumab Letrozole Anastrozole Lapatinib Trastuzumab Exemestane A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Active, not recruiting
NCT03529110 Phase III Trastuzumab deruxtecan Ado-trastuzumab emtansine DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] Active, not recruiting
NCT02025192 Phase I Capecitabine + Trastuzumab + Tucatinib Trastuzumab + Tucatinib Capecitabine + Tucatinib A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Completed
NCT00796978 Phase II Trastuzumab Trastuzumab in Treating Older Women With Early-Stage Breast Cancer Completed
NCT03929666 Phase II Fluorouracil + Leucovorin + Oxaliplatin + ZW25 Cisplatin + Fluorouracil + Leucovorin + ZW25 Capecitabine + Cisplatin + ZW25 A Safety and Efficacy Study of ZW25 Plus Combination Chemotherapy in HER2-expressing Gastroesophageal Adenocarcinoma Recruiting
NCT03674112 Phase II Pertuzumab + Trastuzumab A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer Active, not recruiting
NCT04143711 Phase Ib/II DF1001 DF1001 + Pembrolizumab Study of DF1001 in Patients With Advanced Solid Tumors Recruiting
NCT02124148 Phase I Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Completed